drugset / Trial / NCT02054702
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
Phase 3
Completed
97 enrolled
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to explore changes in efficacy, cognitive functioning, and safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia
Timeline
- Start
- 2014-02
- Primary completion
- 2014-06
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | 20 mg | Oral |
| Subject | Brexpiprazole | Small molecule | 4 mg | Oral |